Abacus FCF Real Assets Leaders ETF (BATS: ABLD)

Últimas noticias sobre Abacus FCF Real Assets Leaders ETF (BATS:ABLD)

Abacus FCF Real Assets Leaders ETF

Industrials

Real Estate

Energy

Basic Materials

Consumer Defensive

Consumer Cyclical

Other

To pursue its investment objective, the Fund invests, under normal market circumstances, at least 80 percent of its net assets (plus any borrowings for investment purposes) in component securities of the Underlying Index. The Underlying Index is sponsored and maintained by FCF Indexes LLC (the Index Provider), an affiliate of FCF Advisors LLC, the Funds investment adviser. The Index Provider currently classifies the following sectors as within the Real Assets Industry Group, each as defined by a third-party industry classification system: real estate related sectors; infrastructure related sectors; commodities related sectors; and natural resources related sectors; and utilities related sectors.

Exxon Mobil Corp Com

Chevron Corp.

Shell Plc (ADR)

Bhp Group Ltd

Honeywell International Inc.

Kinder Morgan, Inc. Class P

Energy Transfer LP

Simon Property Group Inc

Total Sa Adr

Mplx Lp

Shell Plc

Oneok Inc

Bp Plc ADR

Siemens ADR

Watsco Inc

Lamar Advertising Co

Public Storage

Cubesmart Real Estate Investment Trust

Cheniere Energy Partners Lp

Emerson Electric Co.

Gaming And Leisure Properties Inc Reit

Plains All American Pipeline Lp

VINCI SA

Shell.Oil

Earnings

Equities

Large Cap

News

Guidance

Movers

ABLD

AstraZeneca PLC ADRhedged Shell plc ADRhedged

SHEH

SHEL

Shell supera expectativas con ganancias ajustadas de 5580 M$, sube en Bolsa y lanza recompra de acciones de 3500 M$.

Shell (SHEL) sube tras reportar ganancias ajustadas un 52 % mayores en el primer trimestre

WIIM

BRCC

BRC shares are trading lower after the company announced it has priced a $35 million public offering of common stock.

ACTU

Actuate Therapeutics Initiates Planning Of Phase 2 Trial Of Elraglusib In Children, Adolescents, And Adults With Refractory/Resistant Ewing Sarcoma

HYPR

Hyperfine shares are trading higher after the company announced the first commercial sales of its Swoop system, powered by Optive AI software.

Actuate Therapeutics Announces End Of Phase 1 Portion Of Clinical Study Evaluating Elraglusib Monotherapy Or In Combination With Irinotecan, Irinotecan Plus Temozolomide, Or With Cyclophosphamide Plus Topotecan In Pediatric Patients With Refractory Malignancies

Offerings

NioCorp Prices $45.0M Public Offering Of 13,850,000 Shares At $3.25/Share

IQST

IQSTEL Jun. Revenue $27.3M, Up From $23.7M In May; Reports Prelim. 1H Revenue Of $128.8M

Swiss pharmaceutical giant Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported second-quarter 2025 earnings on Thursday and raised its full-year earnings forecast.
Quarterly sales reached $14.05 billion, almost in line with the analysts&#8217; consensus <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimate of $14.06 billion</a>.
Net sales <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-reports-strong-q2-double-digit-sales-growth-and-core-margin-expansion-raises-fy-2025-core-operating-income-guidance" rel="noreferrer noopener">grew</a> 12% year over year (+11% on constant currency or cc) with core operating income up 20% to $5.93 billion (+21% on constant currency).
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46292859/novartis-gets-swiss-approval-for-first-malaria-drug-for-babies" rel="noreferrer noopener">Novartis Gets Swiss Approval For First Malaria Drug For Babies</a>
Sales growth driven by performance from breast cancer treatment, Kisqali ($1.18 billion, +64% cc), Entresto ($2.36 billion, +22% cc), multiple sclerosis drug, Kesimpta ($1.08 billion, +33% cc), Scemblix ($298 million, +79% cc), Leqvio ($298 million, +61% cc), and Pluvicto ($454 million, +30% cc).
Novartis reported adjusted earnings of $2.42 per share, beating the consensus of $2.38.
The company also announced a substantial share buyback program. Novartis said it is initiating a share buyback of up $10 billion to be completed by year-end 2027.
&#8220;Our robust balance sheet and confidence in our mid- and long-term growth enable us to initiate an up-to $10 billion share buyback as part of our commitment to balanced capital allocation,&#8221; stated CEO Vas Narasimhan in a statement on Thursday.
Earlier in July, Novartis released topline results from the Phase 3 GCAptAIN study evaluating Cosentyx (secukinumab) for newly diagnosed or relapsing <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">giant cell arteritis (GCA)</a>.
The study evaluated Cosentyx with a 26-week steroid taper and compared it to a placebo plus a 52-week steroid taper.&nbsp;Cosentyx did not demonstrate a statistically significant improvement in sustained remission at <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46243947/novartis-cosentyx-fails-late-stage-giant-cell-arteritis-trial" rel="noreferrer noopener">Week 52 compared to placebo</a>.
<h2 class="wp-block-heading">Outlook</h2>
For fiscal year 2025, Novartis reaffirms that net sales will grow in the high single digits. 2025 core operating income is expected to grow in the low teens, compared to the low double <a target="_blank" href="https://www.benzinga.com/25/04/45075714/novartis-q1-earnings-beat-street-view-ceo-confident-to-deliver-upgraded-2025-guidance" rel="noreferrer noopener">digits forecasted earlier</a>.
&#8220;We continue to assume Entresto US generic entry in mid-2025 for forecasting purposes, though the timing of generic entry is subject to ongoing IP and regulatory litigation,&#8221; Novartis said in the release.
<h2 class="wp-block-heading">Management Update</h2>
In a separate announcement, Novartis provided a key leadership update: Chief Financial Officer Harry Kirsch will <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-appoints-mukul-mehta-chief-financial-officer-harry-kirsch-retires-after-22-years-company" rel="noreferrer noopener">retire</a> in March 2026, concluding an impressive 22-year tenure at the company, including 12 years in the CFO role since 2013.
He will be succeeded by Mukul Mehta, who currently serves as the company&#8217;s head of business planning and analysis, digital finance, and tax.
Price Action: NVS stock is trading lower by 1.71% to $116.35 during the premarket session at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46463670/supermicro-launches-new-ai-servers-with-intel-xeon-6-chips" target="_blank" rel="noreferrer noopener">Supermicro Launches New AI Servers With Intel Xeon 6 Chips</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Buybacks

Management

General

Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback

Nano Labs shares are trading higher after the company announced it has appointed a new CEO to lead the global crypto reserve strategy of its subsidiary.

Morgan Stanley analyst Kristine Liwag maintains Teledyne Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDY#NYSE">TDY</a>) with a Equal-Weight and raises the price target from $535 to $580.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Teledyne Technologies, Raises Price Target to $580

ATHR

Aether Holdings' Alpha Edge Media Acquires Digital Asset Research And Publication, AltcoinInvesting.co

BPMC

Trading Halt: Halt status updated at 8:45:00 AM ET: Quotation Resumption: News and Resumption Times

Morgan Stanley analyst Kristine Liwag maintains Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Overweight and raises the price target from $405 to $550.

Morgan Stanley Maintains Overweight on Curtiss-Wright, Raises Price Target to $550

Stock Split

LCID

Lucid Files Preliminary Proxy Statement To Initiate Plan For 1-for-10 Reverse Stock Split

NUWE

Nuwellis shares are trading lower after the company announced it has terminated its REVERSE-HF clinical trial to prioritize resources and redirect investment.

INSE

Inspired Entertainment Expands Long-Term Partnership With William Hill To Deliver Comprehensive Upgrade To William Hill's Virtual Sports Offering Across Its UK Retail Estate

OKLO

Oklo shares are trading higher after the company completed the U.S. Nuclear Regulatory Commission's pre-application readiness assessment for Phase 1 of its combined license application for the Aurora Powerhouse.

Stifel analyst Jeffrey Stantial maintains Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) with a Hold and raises the price target from $81 to $92.

MCRI

Stifel Maintains Hold on Monarch Casino & Resort, Raises Price Target to $92

B. Riley Securities analyst Mike Crawford maintains TTM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTMI#NASDAQ">TTMI</a>) with a Buy and raises the price target from $36 to $50.

TTMI

B. Riley Securities Maintains Buy on TTM Technologies, Raises Price Target to $50

BTCT

BTC Digital Announces Transformative, Strategic Shift To Fully Embrace Ethereum As Core Asset And Operational Foundation; Closes $6M Financing Round, Adds New $1M ETH Position

Truist Securities analyst Matthew Coad maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Buy and raises the price target from $58 to $72.

AFRM

Truist Securities Maintains Buy on Affirm Holdings, Raises Price Target to $72

Comments

Abacus FCF Real Assets Leaders ETF

Noticias

Últimas noticias sobre Abacus FCF Real Assets Leaders ETF (BATS:ABLD)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL